Buscar
Mostrando ítems 11-20 de 23
Artículo
The tumour microenvironment as an integrated framework to understand cancer biology
(Elsevier Ireland Ltd, 2019)
Cancer cells all share the feature of being immersed in a complex environment with altered cell-cell/cell-ex tracellular element communication, physicochemical information, and tissue functions. The so-called tumour mic ...
Artículo
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
(Nature publishing group, 2018)
Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis ...
Artículo
SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
(Springer, 2015)
Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually ...
Artículo
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
(Springer, 2018)
Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They difer from other primary tumours in their ...
Artículo
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
(Springer, 2019)
Although the metastasic breast cancer is still an incurable disease, recent advances have increased signifcantly the time to progression and the overall survival. However, too much information has been produced in the ...
Artículo
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
(Springer, 2020)
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which ...
Artículo
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
(2020)
Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed ...
Artículo
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
(BMC, 2019)
Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 ...
Artículo
New horizons in breast cancer: the promise of immunotherapy
(Springer, 2019)
Immunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly ...
Artículo
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor-positive, HER2-negative, node-negative early-stage breast cancer
(Taylor and Francis Group, 2015)
Purpose: Improved understanding of risk of recurrence (ROR) is needed to reduce cases of recurrence and more effectively treat breast cancer patients. The purpose of this study was to examine how a gene-expression profile ...